

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : G01N 27/00	A2	(11) International Publication Number: WO 00/34763 (43) International Publication Date: 15 June 2000 (15.06.00)
(21) International Application Number: PCT/US99/29352 (22) International Filing Date: 10 December 1999 (10.12.99) (30) Priority Data: 60/111,955 11 December 1998 (11.12.98) US 09/321,893 28 May 1999 (28.05.99) US (71) Applicant (for all designated States except US): THE UNIVERSITY OF BRITISH COLUMBIA [CA/CA]; 2194 Health Sciences Mall, Vancouver, British Columbia (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): DOLPHIN, David [CA/CA]; 4464 West 12 Avenue, Vancouver, British Columbia V6R 2R2 (CA). PENG, Xuejun [CN/CA]; 501-2725 Melfa Road, Vancouver, British Columbia V6T 1N4 (CA). STERNBERT, Ethan, D. [US/CA]; 3837 West 4th Avenue, Vancouver, British Columbia V6R 1P8 (CA). (74) Agents: LAU, Kawai et al.; Morrison & Foerster LLP, 2000 Pennsylvania Avenue, N.W., Washington, DC 20006-1888 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: SEPARATION OF PHOTSENSITIZER ISOMERS AND STEREOISOMERS BY LASER-INDUCED FLUORESCENCE CAPILLARY ELECTROPHORESIS (57) Abstract A method for the separation of isomers and stereoisomers of photosensitizers by Laser-Induced Fluorescence Capillary Electrophoresis has been developed. The limits of detection are 2.06×10^{-6} M, and the relative standard deviation for the separation was 2.90 % to 4.64 %. Benzoporphyrin derivative mono and diacid (BPD-MA, BPD-DA) enantiomers can be quantitatively determined in the range of 10^{-2} to 10^{-5} mg mL ⁻¹ . In comparison with HPLC, CE has better resolution and efficiency. This separation method was successfully applied to the BPD enantiomers obtained from a matrix of bovine serum and from liposomally formulated material as well as from studies with rat, dog and human microsomes.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**SEPARATION OF PHOTSENSITIZER ISOMERS AND
STEREoisomers BY LASER-INDUCED
FLUORESCENCE CAPILLARY ELECTROPHORESIS**

Related Applications

The present application claims the benefit of U.S. Provisional Application 60/111,955, filed 11 December 1998, and U.S. Patent Application 09/321,893, filed 29 May 1999, which are hereby incorporated by reference in their entireties, as if fully set forth.

Field of the Invention

The invention relates to the use of capillary electrophoresis separation, as well as laser-induced fluorescence to aid in detection, of isomers and stereoisomers of photosensitizer molecules. For example, these separation methods permit all four enantiomers of BPD-MA and the two of BPD-DA to be completely separated with baseline separation with high resolution and efficiency. The use of laser-induced fluorescence detection greatly improves the analytical sensitivity and selectivity of CE of BPDs. The invention is well suited as a rapid and reliable method for the separation of BPD monoacid and diacid enantiomers in a preparative or analytical application. Of particular utility is the potential for use as an analytical method with clinical samples.

Description of the Related Art

Photodynamic therapy (PDT) is based on the observation that some photosensitizers accumulate somewhat selectivity in tumor tissue where they can be activated by light at wavelengths in the visible region. The photosensitizers absorb photons of visible light and use the absorbed energy to generate singlet oxygen, which is considered responsible for most of the damage leading to tumor cell death and

5 BPD-MA is a novel second-generation photosensitizer for PDT which exhibits
lower skin phototoxicity than Photofrin (Richter et al. (1987)) which has already been
approved by Health Boards around the world. BPD-MA has been shown to be
effective for the treatment of cutaneous lesions; as a promising agent for bone marrow
purging and for the treatment of leukemia (Jamieson et al. (1990)), as an antiviral
10 agent for decontamination of blood and blood products (Neyndorff et al. (1990)) and
most recently for the treatment of age related macular degeneration of the eye (Miller
et al. (1993)).

Nearly 60% of the most frequently prescribed drugs in the United States possess one or more asymmetric centers in the drug molecule. The physiological effects of enantiomers of these racemic drugs have not always been examined. To ensure the safety and efficacy of currently used and newly developed drugs, it is important to isolate the enantiomers and to examine each one separately. Accurate assessment of enantiomeric purity of substances is critical to investigate their toxicological and pharmacological effects and to study pharmacokinetic profiles.

SUBSTITUTE SHEET (RULE 26)

Beukeveld et al. (1994)), porphyrin dimers and trimers (Owens et al. (1996)), porphyrin isomers (Richter et al. (1992) and Udagawa et al. (1982)), and some porphyrin enantiomers (Kimmitt et al. (1992) and Walker et al. (1988)). The large number of biological samples that need to be assayed during a typical pharmacokinetic study and the labor-intensive procedures in these HPLC techniques; required alternative methodologies for this kind of separation. Capillary electrophoresis (CE) is not new (Hjerten et al. (1967) and Jorgenson et al. (1981)) and there have been numerous subsequent studies (Wallingford and Ewing (1988); Pietta et al. (1994); Morin et al. (1993); Honda et al. (1990); Honda et al. (1989); and Hoffstetter-Kuhn et al. (1991)). The good reproducibility, sensitivity, rapidity, ease of automation and small sample requirements of CE have made it a promising bioanalytical technique (Kuhn et al. (1993)) for the separation of porphyrins and their analogues (Kuhn et al. (1993); Yao et al. (1996); Weinberger et al. (1990); Liu et al. (1995); Bowser (1996); and Bowser et al. (1997)). It has been especially useful in the separation of porphyrins because porphyrin fluorescence permits detection at low concentration.

Given the importance of BPDs and other photosensitizers in PDT and the desire to prepare specific stereoisomers for pharmaceutical, research and commercial/industrial applications, the present invention relates to a new CE method for the separation of isomers, stereoisomers and regioisomers of such photosensitizers.

Summary of the Invention

The invention is directed to the use of capillary electrophoresis (CE) methods for the rapid and reliable separation of photosensitizer isomers and stereoisomers, including regioisomers, diastereoisomers and enantiomers, which can then be used in photodynamic therapy (PDT). In particular, laser-induced fluorescence mediated detection is used in combination with CE methods to improve the sensitivity and selectivity in the separation of stereoisomers of BPDs. Additionally, the methods of the invention can be used to completely separate with baseline separation enantiomers of BPDs (as presented in U.S. Patent 5,171,749, which is hereby incorporated by reference as if fully set forth) as well as the derivatives of these compounds, especially

the four enantiomers of BPD-monoacid (BPD-MA) and the two of BPD-diacid (BPD-DA), with high resolution and efficiency. Additional BPDs for separation are EA6 (as set forth in related application 08/852,494, which is hereby incorporated by reference as if fully set forth) and B3 (as set forth in related application 09/265,245, which is hereby incorporated by reference as if fully set forth). In addition to the BPD's, the separation methods are applicable to other photosensitizers, including, but not limited to, chlorins, purpurins, such as tin ethyl etiopurpurin, pthalocyanines, such as pthalocyanine tetrasulfonate, pheophorbides, such as pyropheophorbides (HPPH), chlorophylls, benzoporphyrins, porphyrins and metalloporphyrins. Other photosensitizers to which the methods may be applied are found in the article entitled "A Compilation of Singlet Oxygen Yields from Biologically Relevant Molecules" by Robert W. Redmond and Janet N. Gamlin (*Photochemistry and Photobiology*, 1999, 70(4): 391-475, which is incorporated herein in its entirety.

The invention is also directed to methods of separating isomers, regioisomers and/or stereoisomers as a preparative or analytical application. Because of superiority over known HPLC methods, the preparative or analytical applications of the invention include automated versions of the instant CE methods as well as versions utilizing a smaller sample size over traditional HPLC separation methods. Of particular preference is the use of the instant methods for the analysis of clinical samples of material containing BPDs.

Additionally, the invention includes the use of borate as a buffering system and a chiral selector, such as cholate, for the separation of porphyrin compounds, including metalloporphyrins, porphyrin multimers and isomers, as well as the stereoisomers of such compounds. Borate and cholate can dynamically interact and complex with the BPD enantiomers and influence their electrophoretic properties and migration behavior. Particularly preferred conditions in such separations include the use of a capillary of 50 μ m inner diameter and a 37 cm length (30 cm to detector), a field strength of +20 KV, a separation temperature of 20°C, a pH of 9.2, a borate concentration of 300 mM, 25 mM sodium cholate as a chiral selector, and 10% acetonitrile. A preferred baseline separation time is within 20 minutes.

Moreover, and beyond complete separation of enantiomers, the invention

encompasses methods of separating the stereoisomers of different compounds, the regioisomers of a given compound, as well as the enantiomers of a given compound.

Brief Description of the Drawings

5 The present invention will be more clearly understood by referring to the following drawings:

Fig. 1 Structures of the stereoisomers of BPD-MA and BPD-DA

10 Benzoporphyrin derivative monoacids (BPD-MA, **Ia-1**, **Ia-2**, **Ib-1**, **Ib-2**) and benzoporphyrin derivative diacid (BPD-DA, **II-1**, **II-2**). I and II designate BPD monoacid and diacid, respectively; a and b represent regioisomers; and 1 and 2 represent enantiomers.

Fig. 2 Structures of chiral additives

15 Hydroxypropal- β -cyclodextrin (**III**, $n=2$, $R_1=R_2=H$, $R_3=\text{hydroxypropyl}$); heptakis (2,6-di-O-methyl)- β -cyclodextrin (**III**, $n=2$, $R_1=R_3=\text{methyl}$, $R_2=H$); β -cyclodextrin (**III**, $n=2$, $R_1=R_2=R_3=H$); γ -cyclodextrin (**III**, $n=3$, $R_1=R_2=R_3=H$); cholic acid, sodium salt (**IV**, $R_1=R_2=R_3=OH$, $R_4=ONa$); deoxycholic acid, sodium salt (**IV**, $R_1=R_3=OH$, $R_2=H$, $R_4=ONa$); taurocholic acid, sodium salt (**IV**, $R_1=R_2=R_3=OH$, $R_4=NH(CH_2)SO_3Na$); taurodeoxycholic acid, sodium salt (**IV**, $R_1=R_3=OH$, $R_2=H$, $R_4=NH(CH_2)_2SO_3Na$); β -exin (**V**); salicin (**VI**); rifamycin SV, sodium salt (**VII**); (+)-
20 rutin hydrate (**VIII**); glycyrrizic acid (**IX**).

Fig. 3 UV-Vis and Fluorescence spectra of BPD-MA and BPD-DA

25 a. UV-vis spectra, 1.0×10^{-3} mg ml⁻¹ BPD-MA. b. Fluorescence emission spectra, BPD-MA 1.25×10^{-4} mg ml⁻¹ at pH 9.2, 300 mM borate, 25 mM Cholate and 10% acetonitrile solution. BPD-DA exhibits similar spectra.

Fig. 4 Effect of buffer pH on BPD-MA and BPD-DA separation

30 a. pH 8.05, b. pH 8.60, c. pH 9.2, d. pH 9.60. 300 mM borate and 25 mM sodium cholate and 10% acetonitrile. BPD-DA 2.5×10^{-2} mg ml⁻¹, respectively. Em. 694 nm/Ex. 488 nm. Data 5 Hz. +20KV, 37 cm, 20 °C, electrokinetic sampling 2.0 s.

Identification of peaks: 1, Ia-1; 2, Ib-1; 3, Ia-2; 4, Ib-2; 5, II-1; 6, II-2.

Fig. 5 Effect of electrolyte concentration on BPD-MA and BPD-DA separation

a. 40 mM, b. 80 mM, c. 120 mM, d. 160 mM, e. 200 mM, f. 240 mM, g. 280 mM, h. 300 mM, i. 320 mM, j. 360 mM. borate (pH 9.2). Each contained 25 mM sodium cholate and 10% acetonitrile. BPD-DA 2.5×10^{-2} mg ml⁻¹, respectively. Em. 694 nm/Ex. 488 nm. Data 5 Hz. +20 KV, 37 cm, 20°C, electrokinetic sampling 2.0 s. Identification of peaks is the same as in Figure 4.

Fig. 6 Effect of sodium cholate on BPD-MA and BPD-DA separation

a. 0 mM, b. 10 mM, c. 15 mM, d. 20 mM, e. 25 mM, f. 30 mM, g. 35 mM, h. 40 mM sodium cholate, pH 9.2, 300 mM borate and 10% acetonitrile. BPD-DA 2.5×10^{-2} mg ml⁻¹, respectively. Em. 694nm/Ex. 488 nm. Data 5 Hz. +20KV, 37 cm, 20°C, electrokinetic sampling 2.0 s. Identification of peaks is the same as in Figure 4.

15

Fig. 7 Effect of acetonitrile

a. 0%, b. 5%, c. 10%, d. 15%, e. 20% acetonitrile, pH 9.2, 300 mM borate and 25 mM sodium cholate. BPD-DA 2.5×10^{-2} mg ml⁻¹, respectively. Em. 694 nm/Ex. 488 nm. Data 5 Hz. +20 KV, 37 cm, 20°C, electrokinetic sampling 2.0 s. Identification of peaks is the same as in Figure 4.

20

Fig. 8 Separation of BPD enantiomers by HPLC and CE

HPLC: a. BPD-MA/BPD-DA b. BPD-DA, c-BPD-MA. Elute is hexane: ethanol (80:20) containing 0.3% TTA. 0.7 ml min⁻¹ flow. Injection volume 50 µl of 0.1 mg ml⁻¹ of BPD-MA and BPD-DA. Detection at 420 nm. 1, Ia-2, 2, Ib-2, 3, Ia-1, 4, Ib-1, 5, II-2, 6, II-1.

25

CE: d. pH 9.2, 300 mM borate and 25 mM sodium cholate. BPD-MA/BPD-DA 2.5×10^{-2} mg ml⁻¹, respectively. Em. 694 nm/Ex. 488 nm. Data 5 Hz. +20 KV, 37 cm, 20°C, electrokinetic sampling 2.0 s. Identification of peaks is the same as in Figure 4.

30

Fig. 9 Electrophoregram of BPD enantiomers

Liposomally formulated BPD-MA incubated with (a) dog, (b) human, and (c) rat liver microsomes for 120 min were used as samples. Identification of peaks is the same as in Figure 4. pH 9.2, 300 mM borate and 25 mM sodium cholate. Em. 694nm/Ex. 488 nm. Data 5 Hz. +20KV, 37 cm, 20°C, electrokinetic sampling 2.0 s.

Fig. 10 Chiral Separation of Benzoporphyrin Derivative Mono-Acid (BPD-MA) Regioisomers

Electrolyte: pH 9.2, 280 mM borate and 30% acetonitrile and 7 mM Sodium Dodecyl Sulfate (SDS); Sample: BPD-MA 25 ng ml⁻¹, +20KV, 37 cm capillary length, 20°C. Pressure sampling 3.0s (20 psi). Em. 694 nm/Ex. 442nm. Data 5 Hz.

Fig. 11 Chiral Separation of Diethylglycol Diester Benzoporphyrin Derivative (DEG-BPD, or EA6) Enantiomers

Electrolyte: pH 9.2, 80 mM borate and 30% acetonitrile and 150mM sodium cholate. Sample: DEG-BPD 0.01 mg ml⁻¹, +25 KV, 37 cm capillary length, 20°C. Pressure sampling 3.0s (20 psi). Em. 694 nm/Ex. 442nm. Data 5 Hz.

Fig 12 Separation of 2-(1-hexyloxyethyl)-2-devinylpyropheophorbide-a (HPPH) Diastereoisomers

Electrolyte: pH 9.2, 240 mM borate and 30% acetonitrile + 1.5mM SDS. Sample: HPPH 0.01 mg ml⁻¹. +20 KV, 37 cm capillary length, at 20°C. Electrokinetic sampling 2.0s (+10 KV). Em. 694nm/Ex. 488 nm. Data 5 Hz.

Fig. 13 Chiral Separation of Tin Etiopurpurin Enantiomers

Electrolyte: pH 9.2, 160 mM borate and 10% acetonitrile with 5 mM sodium cholate and 15mM cetyltrimethylammonium bromide. Sample: 0.01 mg ml⁻¹ tin etiopurpurin. -25KV, 37 cm capillary length. 20°C, Pressure sampling 3.0s (20 psi). Em. 694 nm/Ex.442 nm. Data 5 Hz.

Fig. 14 Separation of Benzoporphyrin Derivative Mono-Acid and Mono-Acid Ethyl

(BPD-MA and BPD-MAe) Regioisomers

Electrolyte: pH 9.2, 240 mM borate and 30% acetonitrile and 10 mM SDS. Samples: 75 ng ml⁻¹ BPD-MA + 25 ng ml⁻¹ BPD-MAe. +20KV, 37 cm capillary length, 20°C. Pressure sampling 3.0s (20 psi). Em. 694 nm/Ex. 442nm. Data 5 Hz.

5

Fig. 15 Separation of Phthalocyanine Tetrasulfonate Isomers

Electrolyte: pH 9.2, 120 mM borate with 50% acetonitrile and 10mM SDS. Sample: 2.5 mg ml⁻¹ phthalocyanine tetrasulfonate. +20 KV, 37 cm capillary length, 20°C. Pressure sampling 3.0s (20 psi). UV detection at 214 nm. Data 5 Hz. Peaks 1-8 denote isomers.

10

Detailed Description of the Invention

The present invention embraces methods of using capillary electrophoresis (CE) to separate isomers, regioisomers and/or stereoisomers of photosensitizer molecules, including separating with baseline separation, defined as no detectable overlap between the compounds being separated during elution. Preferred methods include using laser-induced fluorescence to improve detection and hence separation of the stereoisomers. These methods are of great utility in isolating BPD enantiomers while also offering greater flexibility for automation and use of smaller sample size over other separation methods. The most preferred use of the instant methods is for the isolation of the enantiomers of BPD-MA and BPD-DA. In addition to the BPDs, the separation methods are applicable to other photosensitizers, including, but not limited to, chlorins, purpurins, such as tin ethyl etiopurpurin, phthalocyanines, such as phthalocyanine tetrasulfonate, pheophorbides, such as pyropheophorbides (HPPH), chlorophylls, benzoporphyrins, porphyrins and metalloporphyrins. Preferred photosensitizers include tin etiopurpurin, phthalocyanine tetrafulfonate, and HPPH. Other photosensitizers to which the methods may be applied are found in the above referenced article by Robert W. Redmond et al. (1999).

30

Preferred embodiments of the invention includes the use of borate as a buffering system and cholate as a chiral selector. Moreover, the invention is not

limited to the complete separation of enantiomers. Instead, the methods of the invention may be used under conditions where the separation is sufficient to separate different compounds, to separate the regioisomers of a given compound, or to separate the enantiomers of a given compound. When the compounds to be separated do not have chiral centers, however, the inclusion of a chiral selector, such as cholate is not required.

The separation methods of the invention are particularly useful for chlorin-like photosensitizer, such as BPD-MA. As used in the clinic, BPD-MA consists of an equal mixture of the two regioisomers (Ia, Ib). Each regioisomer consists of a pair of enantiomers (Ia-1, Ia-2; Ib-1, Ib-2) as shown in Figure 1. The principal metabolite is the diacid which consists of two enantiomers (II-1, II-2). Tissue distribution studies and efficacy of the regioisomers have been reported (Richter (1991); Woodburn (1992); and Richter et al. (1988)). BPD-DA is composed of two enantiomers (Figure 1).

The compounds have the same chromophore and identical absorption spectra (Figure 3a) with a characteristic major broad peak in the Soret region (420 nm) and several other peaks at longer wavelengths. The most interesting long wavelength peak, in terms of applications in PDT, is the peak at 688 nm (in organic solvents). Extinction coefficients were determined at 430 nm in a buffer solution of 300 mM borate containing 10% acetonitrile and 25 mM sodium cholate pH 9.2 and found to be 61,000 $M^{-1}cm^{-1}$ and 75,200 $M^{-1}cm^{-1}$ for BPD-MA and BPD-DA, respectively. An emission spectrum is also shown in Figure 3b with a characteristic emission at about 692 nm, near red (Q-band), with a Stokes shift of ~ 4 nm for fluorescence. Given the above, there are no apparent mechanistic difference in photo absorption, and hence BPD mediated damage, between the various stereoisomers of each BPD compound. As such, there is no gain in photo absorption by use of any particular BPD enantiomer.

At low pH the free base porphyrin pyrroles can be protonated to yield the PH_3^+ or PH_4^{2+} forms. At pH greater than about 3.0, the free bases are neutral, and only the side chain propionic acid residues are protonated. At higher pH, propionic acid side chains can be ionized to give a P^- for BPD-MA or P^{2-} for BPD-DA. The charges on

these compounds play an important role in their separation by capillary electrophoresis.

Capillary electrophoresis

5 Separation by capillary electrophoresis is based on differential mobilities. Experimental parameters which affect mobility include capillary inner diameter and length, separation voltage, temperature, buffer type and concentration, pH, ionic strength, chiral selector type and concentration, organic solvent type and amount in the electrolyte. Additionally, the size, net charge and the interaction of the analytes
10 with additives affect mobility in capillary electrophoresis. Size and charge of the analytes are related to their molecular mass, structure and the degree of hydration and ionization. The involvement of and interaction between these various parameters are known to the skilled artisan and can be routinely evaluated and optimized. Thus, the selection of appropriate diameters, lengths, voltages, temperatures, buffer types and
15 concentration, pH, ionic strength, chiral selector type and concentration, organic solvent and amount, and other parameters can be selected without undue experimentation

Initial CE parameters to consider include capillary inner diameter and length as well as separation voltage. In evaluating CE for the BPD enantiomers, a +10 KV
20 electrokinetic injection of about 2.0 s was applied, although a range of about +10 to about +25 KV may be used in longer or shorter time intervals. The BPD enantiomers enter the capillary by both migration and by the pumping action of the EOF. Additionally, electrokinetic injection helps concentrate the samples by a "stacking" phenomenon. This injection method is especially beneficial for biological matrices or
25 clinical samples which usually contain large amounts of sodium chloride.

Small inner diameter capillaries can more readily dissipate the joule heating and lower the electric current to result in better separation efficiency. A capillary of about 50 μm inner diameter is preferred for BPD enantiomers, although inner diameters ranging from about 40 to about 75 μm may also be used. Small inner
30 diameters often leads to strong inner capillary wall adsorption along with increased clogging. The detection sensitivity also decreases with a shorter detection window.

Proper conditioning of the capillary and filtration of the running buffer are necessary normal steps before each run.

In order to apply very high electric fields and to decrease the analyte migration time, an appropriate capillary length is necessary. The separation time of the six BPD enantiomers was about 45 min using a capillary of about 57 cm but with a capillary length of about 27 cm, the migration time decreased to about 5 min. As such, a range of lengths from about 27 to about 57 cm may be used. The separation efficiency also decreased since the BPD enantiomers migrated very rapidly past the detection window and did not have sufficient time to separate. A good separation of BPD compounds with an acceptable time profile was obtained using a preferred capillary of about 37 cm in length.

The electroosmotic flow and electrophoretic migration velocity are directly proportional to the field strength applied across the capillary. High field strengths lead to shorter migration times, and a range of about +10 to +25 KV may be used. Three field strengths were compared for the separation of the BPD enantiomers. At about +15 KV, BPD peaks 2 and 3 (the peaks are defined in Figure 4) were overlapping after about 25 min. This may have been due to diffusion. By increasing the voltage to about +20 KV, all six BPD enantiomers were baseline separated within about 15 min. When the separation voltage was increased to about +25 KV, the migration time became shorter but high current and joule heating caused sample plug diffusion and peaks 2 and 3 once again overlapped. In addition, joule heating caused a temperature increase in the inner capillary which resulted in a signal decrease as the BPD fluorescence quantum yields decreased. A field strength of about +20 KV is preferred to give complete baseline separation for all six enantiomers.

Another parameter in CE is temperature. Elevated or reduced separation temperatures can alter running buffer viscosity, electroosmotic flow and analysis time; analyte chemical equilibrium and kinetics in the separation process can also be affected. A range from about 10 to about 35°C may be used. When the temperature was increased from about 25°C to about 35°C, migration time became shorter due to a decrease in the running buffer viscosity which consequently caused the EOF to decrease. At about 35°C, peaks 2 and 3 once again overlapped as a consequence of

joule heating which caused non-uniform temperature gradients, local changes in viscosity and density, and gave rise to zone deformation and subsequent zone broadening. The P/ACE 5500 has a thermostat system range from 5 to 50°C, although at about 15°C, the separation showed significant improvement, and it took about 15 minutes to reach equilibrium. A temperature of about 20°C is preferred as the separation temperature.

Separation by CE is also affected by the buffering system used. Buffer type, concentration, ionic strength, and pH are all parameters to consider, and a variety of buffers may be used. Buffer solutions of pH 11.04, 100 mM 3-(cyclohexylamino)-1-propanesulfonic acid (CAPS); pH 6.76, 30 mM ammonium acetate; pH 2.76, 50 mM citric acid; and pH 9.2, 100 mM borate were tested as electrolytes. The BPD enantiomers were very easily hydrolyzed at high pH using the CAPS buffer (~ pH >11); high concentrations of ammonium acetate buffer usually caused bubbles in the capillary which led to current breaks. This was followed by either separation shut down or excess spiking and signal noise. In citric acid buffer the BPD enantiomers were protonated at the propionic side chain, defeating separation based on the deprotonated state. Since the effective charge(s) are the same for BPD-DA and BPD-MA, the electrophoretic mobility difference is normally very small. Also, at high pH, the EOF was very small and this caused the migration time to become overly long. The result was very poor signal separation due to extensive diffusion.

With borate buffer at about pH 9.2, however, the BPD-DA and BPD-MA enantiomers were completely separated. This, in combination with the ability of borate to form a very stable buffer solution with high buffering capacity and its ability to be used in very high concentrations, made it a preferred choice for use in the instant separation methods. Borate has also been used in other separation systems (Consden et al. (1952); Boeseken (1949); and Landers et al. (1992)). Moreover, studies have shown that BPD-MA decomposed less than 1% in one hour at pH 9.2. Therefore, decomposition (principally hydrolysis) can be ignored within the approximately 15 min analysis time of capillary electrophoresis in borate.

The side chain propionic acid of BPD enantiomers begin to deprotonate when the pH of borate buffer was above about 3.5. As such, pH's above about 3.5 are

preferred in the CE methods of the invention. Preferred pH's range from about 8.05 to about 9.6. BPD-MA enantiomers have one ionizable carboxylic acid group, and BPD-DA has two acidic groups. This charge difference makes BPD-MA and BPD-DA readily separated by CE. In addition to the BPD-MA and BPD-DA separation, differences in pH also alter the dynamic complexation of the BPD enantiomers with chiral selector additives, changing their mobility differences. Figure 4 shows that only BPD-MA and BPD-DA were separated at pH 8.05. The BPD-DA and BPD-MA enantiomers were separated to some extent at pH 8.6, and complete separation was achieved at pH 9.2. By increasing the pH to 9.6, the BPD enantiomers were further distinguished, but their signals decreased due to the higher ionic strength, which adversely influenced fluorescence. Furthermore, migration times also increased due to the high ionic strength which inhibits the EOF.

The effects of borate ionic strength are shown in Figure 5. One disadvantage of increasing ionic strength results from the current increase and excessive joule heating in the capillary. Positive attributes of increasing ionic strength include decreased adsorption of BPD enantiomers on the capillary wall and a suppression of electrophoretic dispersion. It also reduces the EOF and makes the analytes migrate slower to provide better separation. Higher ionic strength also increased the dynamic complexation of borate with the BPD enantiomers and influenced the separation resolution. Ionic strengths ranging from 40 to 360 mM borate may be used in the instant methods, although a range of 120 to 360 mM is preferred, and a range of 200 to 360 mM is more preferred. Most preferred is an ionic strength of 300 mM. At high borate concentrations (above about 360 mM), the buffer solubility and stability deteriorated which caused current breaks and capillary clogging.

Formation constants, free electrophoretic and complexation mobilities with borate and cholate were determined based on dynamic complexation capillary electrophoresis theory (Peng et al. (1997)). The formation constants for dynamic complexation of BPD enantiomers with borate are given in Table 1. Formation constants (K) are in the range of about 11.51 to about 12.51, with little difference between enantiomers showing weak interactions in each case. Based on the equation proposed by Goodall's group (Penn et al. (1994)), the enantiomeric mobility

difference ($\Delta\mu$) is proportional to the difference in the two enantiomeric formation constants (ΔK) and the chiral additive concentration. Although ΔK for BPD-MA **Ia-2** (K about 11.90) and BPD-MA **Ib-1** (K about 11.91) is only 0.01, increasing the borate concentration from about 40 mM to about 360 mM, makes $\Delta\mu$ increase about 9 times and resolution of the two regioisomers increases dramatically. It may also be possible that when borate interacts with BPD enantiomers, the complexes move slower than uncomplexed enantiomers. For example, the free state mobility BPD-MA **Ia-1** is about $-1.95 \times 10^{-5} \text{ cm}^2 \text{V}^{-1} \text{s}^{-1}$ while its complex mobility is about $-2.94 \times 10^{-5} \text{ cm}^2 \text{V}^{-1} \text{s}^{-1}$. This means that when BPD-MA **Ia-1** interacts with borate, the complex has a bigger ratio of charge to size (q/r , where q denotes charge and r denotes radius). Due to this size increase, BPD-MA **Ia-1** becomes more negatively charged when complexed with borate. This leads to longer separation times. All of the other BPD enantiomers behave in a similar manner as BPD-MA **Ia-1**.

Table 1: Formation constant determinations for the BPD enantiomers with borate and cholate

	Borate				cholate			
	$\mu_{ep,A}^a$	$\mu_{ep,Ac}^b$	K^c	R^{2d}	$\mu_{ep,A}^a$	$\mu_{ep,Ac}^b$	K^c	R^{2d}
BPDMA (Ia-1)	-19.53±0.64	-29.39±1.01	11.51±1.68	0.9970	-17.41±0.57	-33.55±1.28	28.50±3.50	0.9848
BPDMA (Ia-2)	-21.15±0.61	-31.21±1.00	11.90±1.71	0.9970	-17.41±0.50	-33.55±1.38	30.54±4.07	0.9801
BPDMA (Ib-1)	-20.36±0.52	-30.33±1.03	11.91±1.78	0.9968	-17.41±0.45	-33.29±1.28	30.90±3.90	0.9815
BPDMA (Ib-2)	-22.27±0.49	-32.38±0.99	12.27±1.76	0.9969	-17.41±0.38	-33.45±1.41	36.53±4.45	0.9768
BPDDA (II-1)	-22.83±0.54	-33.19±1.08	12.48±1.90	0.9965	-17.41±0.41	-30.75±0.53	49.04±3.73	0.9853
BPDDA (II-2)	-25.80±0.53	-36.41±1.07	12.51±1.85	0.9966	-17.41±0.36	-31.15±0.62	48.42±4.14	0.9828

- The electrophoretic mobility of analyte in free form ($\times 10^{-6} \text{ cm}^2 \text{ V}^{-1} \text{ s}^{-1}$).
- The electrophoretic mobility of complex when analyte forms a complex with additive ($\times 10^{-6} \text{ cm}^2 \text{ V}^{-1} \text{ s}^{-1}$).
- The formation constant was calculated according to the methods described in Peng et al. (1997).
- The correlation coefficients (r^2) of the least-squares linear regression analysis of BPD enantiomers formation constant.

Separation of the enantiomers by CE also involves a choice of chiral selectors (additives). These form diastereoisomeric pairs in a dynamic equilibrium complexation process which, if sufficiently distinct electrophoretically, allow for chiral separation. A wide range of chiral selectors for use in CE, such as metal complexes, micellar systems, micromulsions, crown ethers, cyclodextrins, oligosaccharides and proteins are known in the art (Aveline et al. (1995)) and may be used in the instant methods.

For BPD stereoisomers, different additives (shown in Figure 2) HP- β -CD, DM- β -CD, β -CD, and γ -CD, bile salts, β -escin, salicin, sodium rifamycin SV, (+)-rutin hydrate and ammonium glycyrrhizic have been tested as chiral selectors. The bile salts are preferred chiral selector agents. Bile salts are biological surfactants and form small or primary aggregates of 3 to 14 monomers. These aggregates form a type of "inverse micelle" having a negatively charged core and a hydrophobic uncharged surface, which is opposite to that exhibited for sodium dodecyl sulfate (SDS). The amphiphilic nature of bile salts provides both hydrophobic and polar (or electrostatic) sites. The non-polar faces of the monomers aid in solubilizing hydrophobic compounds, and the structurally rigid chiral bile salts selectively interact with BPD enantiomers.

Four sodium bile salts: cholate, taurocholate, deoxycholate and taurodeoxycholate were further tested as chiral selectors. Small changes in their chemical structures (Figure 2) had a significantly impact on the recognition of BPD enantiomers, but all four may be used in the methods of the invention. Sodium cholate had the best separating ability (Figure 6) and is the most preferred chiral selector, although other salts of cholate may also be used. Moreover, a range of bile salt concentrations, ranging from about 10 to about 35 mM may be used. Increasing the sodium cholate concentration from 0 mM to about 10 mM allowed for the separation of BPD-MA and BPD-DA with only partial separation of their enantiomers. By increasing the sodium cholate concentrations to about 15 and then about 20 mM, the two BPD-DA enantiomers gave complete baseline separation within approximately 11 min, while the BPD-MA enantiomers showed four peaks,

two of them overlapping. By further increasing the sodium cholate concentration to about 25 and about 30 mM, complete baseline separation of both the four BPD-MA and the two BPD-DA enantiomers was observed. A preferred sodium cholate concentration for the separation is about 25 mM, although a range from about 15 to about 30 mM. When the sodium cholate concentration was greater than about 30 mM, all peaks were shifted to longer analysis times with deterioration in resolution (Figure 6).

The formation constants (K) of sodium cholate with the BPD enantiomers were determined to be about 28.5, 30.54, 30.90, 36.53, 49.04, 48.42 (Table 1). Differences in the formation constants makes the separation of all six enantiomers possible, and optimization of the cholate concentration allows for optimal separation. The complex mobilities of the enantiomers with cholate have more negative values than the corresponding enantiomers in their free uncomplexed state (Table 1).

Organic solvents can also alter the polarity and viscosity of a buffer electrolyte, resulting in changes to both the electrophoretic mobility and EOF. Organic solvents are also widely used as a solubilizing agent for analytes which are poorly soluble in aqueous solution, for increasing solvation of solutes, and for modifying the affinities of hydrophobic solutes. BPD derivatives undergo self-aggregation in aqueous media, but this can be prevented by adding organic solvent (Aveline (1995)). As such, any organic solvent may be used in the methods of the invention. The effects of acetonitrile, dimethyl formamide (DMF), methanol, dimethyl sulfoxide (DMSO), *n*-propanol and isopropanol were evaluated. It was found that the BPD enantiomers can be baseline separated upon the addition of DMF, isopropanol or acetonitrile. All tested organic solvents exhibited synergetic effects which improved the separation. Figure 7 shows the results of changing acetonitrile concentration in the running buffer. Acetonitrile in amounts from about 10 to about 15% are preferred to enhance separation (Figure 7). Without the addition of acetonitrile or another organic solvent, aggregation prevents separation. When acetonitrile was above about 20%, the running buffer electrolyte became unstable, with both borate and sodium cholate precipitation leading to capillary clogging.

Reproducibility in CE is highly desirable for efficient separation. Thus proper

capillary conditioning methods and analytical procedures are important to maintain a reproducible capillary surface and to obtain reproducible separations. Conditioning refreshes the surface, deprotonates the silanol groups, and removes absorbed impurities. BPD enantiomers exhibit strong adsorption on silica. A sufficiently long
5 rinse time prevents the capillary inner wall from building a contact coating. Too short a rinse time results in the contact coating reducing EOF. This results in longer sample migration times, and causes band broadening and tailing, thus impairing separation. The example section below sets forth a preferred conditioning method, which performed well as shown in Table 2, with relative standard deviation (RSD) only
10 between 2.90% to 4.64%. The contribution of the charged BPD enantiomers to the overall ionic strength of the run electrolyte and the amount of DMSO in the sample can be ignored because of their very low concentrations.

Table 2: Results from linearity studies

Analytes	Equation ^a	Range (mg ml ⁻¹)	R ²	RSD% ^b	DL ^c (x10 ⁻⁶ M)
BPDMA (Ia-1)	Y=103.46X + 0.20	5x10 ⁻² -5x10 ⁻⁵	0.9973	4.64	3.25
BPDMA (Ia-2)	Y=99.827X + 0.24	5x10 ⁻² -5x10 ⁻⁵	0.9986	4.09	2.85
BPDMA (Ib-1)	Y=89.027X + 0.19	5x10 ⁻² -5x10 ⁻⁵	0.9990	3.67	2.56
BPDMA (Ib-2)	Y=117.32X + 0.25	5x10 ⁻² -5x10 ⁻⁵	0.9997	3.12	2.18
BPDDA (II-1)	Y=491.68X + 1.17	5x10 ⁻² -5x10 ⁻⁵	0.9914	3.32	2.36
BPDDA (II-2)	Y=532.57X + 1.37	5x10 ⁻² -5x10 ⁻⁵	0.9910	2.90	2.06

a. Calibration curve equation for BPD-MA enantiomers.

b. Means of ten determinations each, with 95% confidence limits.

c. Detection of limits is the concentration of analytes that give a signal equal to twice the peak-to-peak noise level of the analytes.

High sensitivity laser-induced fluorescence greatly improves the sensitivity and selectivity of BPD stereoisomer separation by CE. Although the smaller inner diameter capillary of about 50 nm resulted in a decrease of analytical signal it also prevents temperature increases due to high currents. The excessive joule heating observed with a 75 nm inner diameter capillary lowers the quantum efficiency of fluorescence due to the increased frequency of collisions at elevated temperature and deactivation by external conversion. The addition of acetonitrile also prevents BPD aggregation and self-quenching and self-adsorption, which otherwise results in an unusual analytical signal.

A wavelength bandpass filter at 690 ± 5 nm may also be used to remove the background noise and other interference. The multiple absorption bands of the BPD derivatives permits the use of a 488 nm laser for excitation. Most matrix (or otherwise contaminating) compounds in clinical samples do not absorb at about 488 nm, nor fluorescence at 690 nm. Matrix influence also can be prevented, to some extent, by using the electrokinetic injection mode.

A calibration curve facilitates CE separation. Calibration graphs for concentrations of 5.0×10^{-5} M to 5.0×10^{-2} M BPD were used for the analysis of BPD enantiomers in field samples. Samples were injected in triplicate, and average peak areas, instead of peak heights, were used to construct the calibration curves. The correlation coefficients (r^2) from a least-squares linear regression analysis of the BPD enantiomers ranged from 0.9814 to 0.9997 and are listed in Table 3. The limits of detection were from 2.06×10^{-6} to 3.25×10^{-6} M for the BPD enantiomers with a signal-to-noise ratio of 2:1 at a detection wavelength of 694 nm. The same day relative standard deviations were from 2.90% to 4.64% ($n=10$).

A comparison of HPLC and CE for the separation of BPD stereoisomers demonstrates a significant superiority in CE. With HPLC, the optimal conditions were found to be hexane:ethanol (80:20, 1% diethylamine), 0.7 mL min^{-1} flow rate and $50 \text{ } \mu\text{L}$ of a 0.1 mg mL^{-1} BPD solution. Using a Chiral Pak AD column, BPD-MA(I), BPD-MA(II) and BPD-DA enantiomers were separated (Figure 8). When BPD-MA and BPD-DA were mixed and injected. BPD-MA (I) and BPD-MA (II)

completely overlapped and BPD-DA partly overlapped with BPD-MA (I, II). The peak shapes were distorted by tailing, and the analytical migration time was as long as 35 min. In comparison to the separation electrophorogram of the BPD enantiomers performed by CE (Figure 8), the CE method made a significantly improvement in resolution. The analytical time was shortened to 13 min. with completely baseline separation of all the BPD enantiomers and sharp peaks were observed without tailing. The resolution and number of theoretical plates (N) per meter of capillary are listed in Table 3. N/m is in the range of 46100 to 115400 in CE. This may be considered as satisfactory, especially compared with chiral HPLC analysis where N/m is no more than 1650.

Table 3: Comparison of the Separation of BPD enantiomers by HPLC and CE

	CE			HPLC		
	t^a (min)	N^b ($\times 10^4$)	Rs^f	t^a (min)	N^b ($\times 10^2$)	Rs^f
BPDMA (Ia-1)	9.38	9.96	8.20 ^c	12.31	11.40	3.72 ^e
BPDMA (Ib-1)	9.95	4.82	2.92 ^d	12.70	6.43	1.79 ^d
BPDMA (Ia-2)	10.17	10.41	---	24.05	16.52	---
BPDMA (Ib-2)	10.64	4.61	---	27.64	5.46	---
BPDDA (I-1)	11.79	11.54	4.17 ^e	11.70	7.49	3.05 ^e
BPDDA (II-2)	12.61	10.48	---	21.69	8.60	---

- Migration time.
- The number of theoretical plates. $N=5.54(t/w_{1/2})^2$
- The resolution of peaks BPD-MA (Ia-1) and BPD-MA (Ia-2)
- The resolution of peaks BPD-MA (Ib-1) and BPD-MA (Ib-2)
- The resolution of peaks BPD-DA (II-1) and BPD-DA (II-2)
- The resolution of two peaks, $Rs=2(t_2-t_1)/(w_2+w_1)$

Figures 10 through 15 illustrate how the CE separation conditions can be adapted to separate isomers, enantiomers, diastereoisomers and regioisomers of a variety of photosensitizers. The conditions used for the separations are given in the Brief Description of the Drawings. The separation of BPD-MA regioisomers is shown in Figure 10, the separation of regioisomers from a mixture of BPD-MA and BPD-Mae is shown in Figure 14, and the separation of phthalocyanine tetrasulfonate isomers is shown in Figure 15. The multi-peak profile in Figure 15 may be a result of contamination of the phthalocyanine sample with trisulfonated material.

The separation of the HPPH (2-(1-hexyloxyethyl)-2-devinylpyropheophorbide-a) diastereoisomers is shown in Figure 12. The separation of enantiomers of tin etiopurpurin is shown in Figure 13. The fact that the fluorescence profile does not show equal amounts of each enantiomer is probably a result of differential quenching by the interaction of the enantiomers with the chiral agent used to facilitate the separation. The separation of enantiomers of diethylglycol diester BPD is shown in Figure 11. It is likely that some of the separations shown could be further improved by titrating each element of the system (ionic strength, buffer type, chiral selector, etc.), as was done for BPD-MA and BPD-DA herein.

Applications

The methods of the instant invention may be used to separate regioisomers and stereoisomers of BPDs and other photosensitizers. Such separation techniques may be used to prepare specific stereoisomers, regioisomers or enantiomers for use in research, testing, or therapeutic applications. Alternatively, the methods may be used in analytical applications to identify particular stereoisomers from mixtures or complex samples. These analytical applications include the use of the instant invention to quantify the amounts of particular stereoisomers in a given sample. These applications can be used in studies of photosensitizer delivery and metabolism in clinical samples of various tissues over time. As such, they are of great potential value in medical and therapeutic applications.

One analytical application is extraction of BPD from bovine serum. The

recovery using acetonitrile (x 3) in CE is about 91.2%. Initial purification of the extracts, such as with a Waters Sep-Pak cartridge, removes most of the matrix components (such as proteins, salts, etc.). After concentration, the samples can be directly injected for CE analysis. The evaporation step is necessary for sample preparation, since this allows for precipitation and removal of additional impurities. The main disadvantage of the sample preparation using a Sep-pack cartridge is the partial hydrolysis to BPD-DA enantiomers if the pH is not well controlled (pH must be maintained between 6.0 and 8.0). An alternative method was developed by replacing the Sep-Pak cartridge with a 0.22 μm solvent filter. A standard solution of liposomally formulated drug (verteporfin, BPD-MA) can be readily separated. Based on these techniques, the metabolites of liposomal formulated BPD-MA incubated with liver microsomes of rat, dog and human were successfully separated (Figure 9).

The following examples are intended to illustrate but not to limit the invention.

Example 1

Materials Used

Capillary Electrophoresis System and Instrumentation

All experiments were performed using a Beckman P/ACE 5500 system consisting of an autosampler, a vacuum injection system, a thermostated capillary compartment (5-50°C) and a UV-Vis detector, Diode Array Detector (DAD) or Laser Induced Fluorescence (LIF) detector with a 3 mW Argon Laser module (488 nm) (Beckman Instruments Inc., Mississauga, Ontario) and a band pass filter 690 ± 5 nm (i.d. 1 inch, ORIEL). Uncoated fused silica capillary columns were obtained from Polymicro Technologies (Phoenix, AZ). Unless otherwise specified, dimension were typically 50 μm i.d., 355 μm o.d. and 37 cm total length (30 cm to detector). The new capillary was treated with 1.0 M NaOH for 15 min followed by a 15 min rinse with deionized distilled water and equilibrated with the electrophoresis running buffer overnight before use. Data collection, processing and analysis were performed using the P/ACETM Station software package (Beckman).

An AMINCO-Bowman series 2 luminescence spectrometer (SLM-AMINCO, Urbana, IL), a 8452A diode array spectrophotometer (Hewlett Packard), a 600E multisolvent delivery HPLC system with 991 photodiode array detector (division of Millipore, USA) were also used. Sep-Pak Cartridges were purchased from Waters (Milford, Massachusetts, USA). A GLC-1 General Laboratory Centrifuge and Microfuge ETM (Beckman) and a Millex[®]-GV Filter Unit, 0.22 μm pore size (Millipore) were also employed.

Synthesis of BPD analogues

BPD-MA and BPD-DA (Figure 1) were synthesized from the Diels-Alder adducts of protoporphyrin and dimethyl acetylene dicarboxylate (Richter et al. (1987)). The time of hydrolysis of the propionic dimethylesters with 25% hydrochloric acid dictates the final ratio between mono- and di-acids that are formed. The separation of the diacids from the monoacid analogues is achieved by chromatography (Richter et al. (1990)). Solutions of BPD-MA and BPD-DA were prepared in dimethyl sulfoxide (DMSO) at a concentration of 10 mg mL⁻¹. The stock solutions were stored frozen below 0°C in the dark. Immediately before use, a fraction of the stock solution was diluted with DMSO to a concentration of 2.0x10⁻² mg mL⁻¹.

Chemicals

Hydroxypropyl- β -cyclodextrin (HP- β -CD), heptakis(2,6-di-O-methyl)- β -cyclodextrin (DM- β -CD), β -cyclodextrin (β -CD), and γ -cyclodextrin (γ -CD) were from Beckman Inc, Mississauga, Ontario and sodium dodecyl sulfate (SDS) from Fisher Inc. The structures of the chiral additives are shown in Figure 2. Taurocholic acid, sodium salt hydrate, (+)-rutin hydrate, deoxycholic acid, sodium salt, monohydrate, glycyrrhizic acid, monoammonium salt hydrate, salicin and Brij 35 were obtained from Aldrich Chem. Co, Milw, WI. Cholic acid, sodium salt, taurodeoxycholic acid, sodium salt, β -escin and rifamycin SV, sodium salt were purchased from Sigma (St. Louis, MO, USA). The buffer stock solutions were pH 11.04, 100 mM 3-[cyclohexylamino]-*n*-propanesulfonic acid (CAPS); pH 9.2, 100

mM $\text{Na}_2\text{B}_4\text{O}_7 \cdot 10\text{H}_2\text{O}$ (Borax); pH 6.8, 100 mM ammonium acetate and pH 2.8, 100 mM citric acid (Sigma, St. Louis, MO, USA). These were diluted to the appropriate concentration before use.

5 All solution were filtered through a 0.22 μm filter prior to use. Water was distilled and deionized with a NANO pure II ultra water system (Barnstead/Thermolyne, Dubuque, IA, USA), DMSO, acetonitrile, 1-propanol, *iso*-propanol and methanol were HPLC grade (Fisher Scientific) and all other chemicals were of analytical grade and used without further purification.

10 Samples

Liposomally formulated benzoporphyrin derivative monoacid ring A (BPD-MA, Verteporfin) was provided by QLT PhotoTherapeutics Inc., Vancouver, Canada. Bovine serum and extracts from microsomes were liposomally formulated BPD-MA incubated with rat, dog and human and were provided by Dr. Julia Levy, Department
15 of Microbiology, University of British Columbia, Vancouver, Canada.

Bovine Serum Preparation

The BPD-MA stock solution (1 mL, 0.1 mg mL^{-1}) was added to bovine serum (1.0 mL) or an acetone blank (1 mL), stirred well, and then acetonitrile (1.0 mL) was
20 added. The mixture was stirred well and centrifuged (5 min at 2000 rpm). The supernatant was collected and the serum was re-suspended and washed twice in acetonitrile. The combined supernatants were filtered using a 0.22 μm filter. Recovery was determined using fluorescence detection. After evaporating the extracts to around 0.5 mL, the final volume was brought to 5.0 mL with water. The solution
25 was then put into a Sep-Pak cartridge and washed with water. The Sep-Pak cartridge was rinsed with acetonitrile (5 x 1 mL). The eluates were evaporated, DMSO (200 μl) was added and the solution stirred and filtered using a 0.22 μm filter. The sample was then ready for CE separation.

30 Example 2

CE Separation Procedures

The instrument was programmed to rinse the capillary at high pressure with 0.2 M NaOH for 5 min, pure water for 5 min. and then the separation buffer for 3 min. Samples were then introduced by a +10 KV electrokinetic injection for 2.0 sec. The separation was conducted in a constant-voltage mode by applying +20 KV across the ends of the capillary with normal polarity. The laser excitation wavelength was 488 nm and the fluorescence detection was monitored at 694 nm (10 nm, 1.0 inch band pass filter). The detector cell window was made by removing the polyimide coating on the capillary. The temperature of the capillary was held at 20°C. Data was collected at 5 Hz. Between runs, the capillary was cleaned and equilibrated with successive 5 min rinses of 1.0 M NaOH and pure water.

Example 3

Separation of BPD-MA from its liposomal formulation

Into a 25 mL bottle containing liposomally formulated BPD-MA (25 mg) was added 12.5 mL of H₂O. After stirring, it was stored in the dark (below 0°C) until use. A sample of this stock solution (5.0 µl) was added to DMSO (950 µl). The solution was stirred well and centrifuged for 5 minutes and filtered using a 0.22 µm solvent filter and then stored in the dark (4°C) until use. 12.5 µl of this solution (2.0 mg mL⁻¹) was added to 25% acetonitrile/water and stirred well. The solution was then transferred into Sep-Pak cartridge and rinsed with 25% acetonitrile/water three times. The Sep-Pak was eluted with methanol (5 x 1.0 mL). The elutes were combined and evaporated under a nitrogen stream and the precipitate was dissolved in DMSO (5.0 mL), filtered using a 0.22 µm filter, and stored in the dark at 4°C. All references cited hereinabove and below are hereby incorporated by reference in their entireties, whether previously specifically incorporated or not.

Having now fully described this invention, it will be appreciated by those skilled in the art that the same can be performed within a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue experimentation.

While this invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications.

This application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth as follows in the scope of the appended claims.

References

Peng, X.; Bowser, M. T.; Britz-Mckibbin, P.; Bebault, G. M.; Morris, J. R.; Chen, D. D. Y. *Electrophoresis* **1997**, *18*, 706-716.

Delaney, T. F.; Glatstein, E. *Comprehensive Therapy* **1988**, *14*, 43.

Sternberg, E. D.; Dolphin, D. *Current Medicinal Chemistry* **1996**, *3*, 239-272.

Richter, A. M.; Kelly, B.; Chow, J.; Liu, D. J.; Towers, G. H. N.; Dolphin, D.; Levy, J. G. *J. Natl. Can. Inst.* **1987**, *79*, 1327.

Jamieson, C. H. M.; McDonald, W. N.; Levy, J. G. *Leuk. Res.* **1990**, *14*, 209-219.

Neyndorff, H. D.; Bartel, D. L.; Tufaro, F.; Levy, J. G. *Transfusion* **1990**, *30*, 485-490.

Miller, H.; Miller, B. *Aich Opthalomol.* **1993**, *111*, 885.

Richter, A. M.; Waterfield, E.; Jian, A. K.; Allison, B.; Sternberg, E. D.; Dolphin, D.; Levy, J. G. *Br. J. cancer* **1991**, *63*, 87-93.

Woodburn, K. W.; Stylli, S.; Hill, J. S.; Kaye, A. H.; Reiss, J. A.; Phillips, D. R. *Br. J. VCancer* **1992**, *65*, 321-328.

Richter, A. M.; Sternberg, E. D.; Waterfield, E.; Dolphin, D.; Levy, J. G., Boston, MA 1988.

Lim, C. K.; Li, F. M.; Peters, T. J. *Journal of Chromatography* **1988**, *429*, 123-53.

Wan, J. R.; Gouterman, M.; Green, E.; Khalil, G. *J. Liquid Chromatogr.* **1994**, *17*, 2045-2056.

Ho, J. W.; Candy, L. Y. F. *J. Liquid Chromatogr.* **1994**, *17*, 549-558.

Sato, H.; Ido, K. L.; Kimura, K. *Clin. Chem.* **1994**, *40*, 1239-1244.

Beukeveld, G. J. J.; Meerman, L.; Huizenga, J. R.; Venekamp-Hoolsema, E. E. A.; Gips, C. H.; Wolthers, B. G. *European J. Clin. Chem. & Clin. Biochem.* **1994**, *32*, 153-159.

Owens, J. W.; Robins, M.; Robinson, R.; Smith, R. *J. Chromatogr. B* **1996**, *682*, 327-

336.

Richter, A. M.; Jain, A. K.; Canaan, A. J.; Waterfield, E.; Sternberg, E. D.; Levy, J. G. *Biochemical Pharmacology* 1992, 43, 2349-58.

Udagawa, M.; Hayashi, Y.; Hirayama, C. *Journal of Chromatography* 1982, 233, 338-42.

Kimmett, S. M.; Whitney, R. A.; Marks, G. S. *Molecular Pharmacology* 1992, 42, 307-10.

Walker, C. J.; Mansfield, K. E.; Rezzano, I. N.; Hanamoto, C. M.; Smith, K. M.; Castelfranco, P. A. *Biochemical Journal* 1988, 255, 685-92.

Hjerten, S. *Chromatogr. Rev.* 1967, 9, 122-219.

Jorgenson, J. W.; Lukacs, K. D. *Clin Chem* 1981, 27, 1551-3.

Kuhn, R.; Hoffstetter-Kuhn, S. *Capillary Electrophoresis Principles and Practice*; Springer-Verlag Berlin Heidelberg: Berlin, 1993.

Yao, Y. J.; Li, S. F. Y. *Journal of Liquid Chromatography & Related Technologies* 1996, 19, 1-15.

Weinberger, R.; Sapp, E.; Moring, S. *J Chromatogr* 1990, 516, 271-85.

Liu, X. H.; Xu, Y.; Ip, M. P. C. *Analytical Chemistry* 1995, 67, 3211-3218.

Bowser, M. T.; Sternberg, E. D.; Chen, D. D. Y. *Analytical Biochemistry* 1996, 241, 143-150.

Bowser, M. T.; Sternberg, E. D.; Chen, D. D. Y. *Electrophoresis* 1997, 18, 82-91.

Richter, A. M.; Cerruti-sola, S.; Sternberg, E. D.; Dolphin, D.; Levy, J. G. *J. Photochem. Photobiol.* 1990, 5, 231.

Wallingford, R. A.; Ewing, A. G. *J. Chromatogr.* 1988, 441, 299-309.

Pietta, P.; Mauri, P.; Bruno, A.; Gardana, C. *Electrophoresis* 1994, 15, 1326.

Morin, P.; Dreux, M.; Andre, P. *J. Chromatogr.* 1993, 628, 161-169.

Honda, S.; Makino, A.; Suzuki, S.; Kakehi, K. *Anal. Biochem.* 1990, 191, 228-234.

Honda, S.; Iwase, S.; Makino, A.; Fujiwara, S. *Anal. Biochem.* 1989, 176, 72-77.

Hoffstetter-Kuhn, S.; Paulus, A.; Gassmann, E.; Widmer, H. M. *Anal. Chem.* 1991, 63, 1541-1547.

Consden, R.; S., W. M. *Nature* 1952, 169, 783.

Boeseken, J. *Adv. Carbohydr. Chem.* 1949, 4, 189.

Landers, J. P.; Oda, R. P.; Schuchard, M. D. *Anal. Chem.* **1992**, *64*, 2846-2851.

Penn, S. G.; Bergstrom, E. T.; Goodall, D. M. *Anal Chem* **1994**, *66*, 2866-73.

Aveline, B. M.; Hasan, T.; Redmond, R. W. *J. Photochem. Photobiol. B Biology* **1995**, *30*, 161-165.

We claim:

1. A method of separating isomers of photosensitizers by a capillary electrophoresis system; which method comprises:

5 separating, after injection of a sample containing said photosensitizers, isomers by said capillary electrophoresis system,

wherein the capillary inner diameter, capillary length, field strength, separation temperature, pH, buffer system, ionic strength, chiral selector, and organic solvent are selected to result in separation of stereoisomers.

10 2. The method of claim 1 wherein said capillary electrophoresis system comprises a laser-induced fluorescence detection system.

15 3. The method of claim 1 or 2 wherein said isomers are selected from the group consisting of regioisomers, stereoisomers, diastereoisomers, enantiomers and mixtures thereof.

20 4. The method of claim 1, 2 or 3 wherein said photosensitizers are selected from the group consisting of benzoporphyrin derivatives (BPDs), chlorins, purpurins, pthalocyanines, pheophorbides, pyropheophorbides, chlorophylls, benzoporphyrins, porphyrins, metalloporphyrins and combinations thereof.

25 5. The method of claim 4 wherein said photosensitizers are selected from the group consisting of tin ethyl etiopurpurin, pthalocyanine tetrasulfonate, and HPPH.

6. The method of claim 4 wherein said photosensitizers are BPDs.

30 7. The method of claim 6 wherein said BPDs are selected from BPD-MA, BPD-DA, BPD-MAe, EA6 or mixtures thereof.

8. The method of any one of claims 1-4, 6 and 7 wherein said separation is

baseline separation.

9. The method of any one of claims 1-4, 6 and 7 wherein said capillary inner diameter is about 50 μm .

10. The method of any one of claims 1-4, 6 and 7 wherein said capillary length is from about 27 to about 57 cm.

11. The method of claim 10 wherein said capillary length is about 37 cm.

12. The method of any one of claims 1-4, 6 and 7 wherein said field strength is from about +15 to about +25 KV.

13. The method of claim 12 wherein said field strength is about +20 KV.

14. The method of any one of claims 1-4, 6 and 7 wherein said separation temperature is from about 15 to about 30°C.

15. The method of claim 14 wherein said separation temperature is about 20°C.


16. The method of any one of claims 1-4, 6 and 7 wherein said pH is from about 8.05 to about 9.6.

17. The method of claim 16 wherein said pH is about 9.2.


18. The method of any one of claims 1-4, 6 and 7 wherein said buffer system is borate.

19. The method of any one of claims 1-4, 6 and 7 wherein said ionic strength is from about 200 to about 360 mM borate.


20. The method of claim 19 wherein said ionic strength is about 300 mM borate.
21. The method of any one of claims 1-4, 6 and 7 wherein said chiral selector is a bile salt.
- 5 22. The method of claim 21 wherein said bile salt is a cholate salt.
23. The method of claim 22 wherein said cholate salt is sodium cholate.
- 10 24. The method of any one of claims 1-4, 6 and 7 wherein said organic solvent is selected from the group consisting of DMF, isopropanol or acetonitrile.
25. The method of claim 24 wherein said organic solvent is acetonitrile.




BPDMA (Ia-1)




BPDMA (Ia-2)




BPDMA (Ib-1)



BPDMA (Ib-2)



BPDDA (II-1)



BPDDA (II-2)

FIG. 1




FIG. 2

3 / 15





FIG. 3

4 / 15

**FIG. 4**

5 / 15




FIG. 5

6/15




FIG. 6




FIG. 7

8 / 15






FIG. 8

**FIG. 9**




FIG. 10




FIG. 11

12 / 15




FIG. 12




FIG. 13




FIG. 14

15 / 15




FIG. 15

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : G01N 27/447		A3	(11) International Publication Number: WO 00/34763
			(43) International Publication Date: 15 June 2000 (15.06.00)
(21) International Application Number: PCT/US99/29352			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 10 December 1999 (10.12.99)			
(30) Priority Data: 60/111,955 11 December 1998 (11.12.98) US 09/321,893 28 May 1999 (28.05.99) US			
(71) Applicant (for all designated States except US): THE UNIVERSITY OF BRITISH COLUMBIA [CA/CA]; 2194 Health Sciences Mall, Vancouver, British Columbia (CA).			
(72) Inventors; and (75) Inventors/Applicants (for US only): DOLPHIN, David [CA/CA]; 4464 West 12 Avenue, Vancouver, British Columbia V6R 2R2 (CA). PENG, Xuejun [CN/CA]; 501-2725 Melfa Road, Vancouver, British Columbia V6T 1N4 (CA). STERNBERT, Ethan, D. [US/CA]; 3837 West 4th Avenue, Vancouver, British Columbia V6R 1P8 (CA).			
(74) Agents: LAU, Kawai et al.; Morrison & Foerster LLP, 2000 Pennsylvania Avenue, N.W., Washington, DC 20006-1888 (US).			Published With international search report.
			(88) Date of publication of the international search report: 12 October 2000 (12.10.00)
(54) Title: SEPARATION OF PHOTSENSITIZER ISOMERS AND STEREOISOMERS BY LASER-INDUCED FLUORESCENCE CAPILLARY ELECTROPHORESIS			
(57) Abstract <p>A method for the separation of isomers and stereoisomers of photosensitizers by Laser-Induced Fluorescence Capillary Electrophoresis has been developed. The limits of detection are 2.06×10^{-6} M, and the relative standard deviation for the separation was 2.90 % to 4.64 %. Benzoporphyrin derivative mono and diacid (BPD-MA, BPD-DA) enantiomers can be quantitatively determined in the range of 10^{-2} to 10^{-5} mg mL⁻¹. In comparison with HPLC, CE has better resolution and efficiency. This separation method was successfully applied to the BPD enantiomers obtained from a matrix of bovine serum and from liposomally formulated material as well as from studies with rat, dog and human microsomes.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

In. ational Application No
PCT/US 99/29352

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 G01N27/447

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CHAN E.: "Capillary electrophoresis analysis of polyhematoporphyrin, a photosensitizer used in dynamic therapy" JOURNAL OF CHROMATOGRAPHY, vol. 636, no. 1, 1993, pages 171-178, XP002139337 abstract	1-3
Y	EP 0 485 370 A (UNIV LELAND STANFORD JUNIOR) 13 May 1992 (1992-05-13) page 3, line 44 -page 10, line 24	1-3
A	DE 41 36 462 A (SCHURIG V.) 6 May 1993 (1993-05-06) column 1, line 45 -column 3, line 28 -/--	1,18

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

5 June 2000

Date of mailing of the international search report

26/06/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Duchatellier, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/29352

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 546 916 A (SEBIA SA) 16 June 1993 (1993-06-16) page 4, line 39 ---	1,22,23
A	US 5 626 757 A (ARMSTRONG DANIEL) 6 May 1997 (1997-05-06) examples 11-18 ---	1
A	STALCUP A M ET AL: "HEPARIN: A CHIRAL MOBILE-PHASE ADDITIVE FOR CAPILLARY ZONE ELECTROPHORESIS" ANALYTICAL CHEMISTRY, US, AMERICAN CHEMICAL SOCIETY, COLUMBUS, vol. 66, no. 19, 1 October 1994 (1994-10-01), pages 3054-3059, XP000478174 ISSN: 0003-2700 abstract -----	1,8

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/29352

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0485370 A	13-05-1992	US 4675300 A	23-06-1987
		CA 1309058 A	20-10-1992
		DE 3650483 D	28-03-1996
		DE 3650483 T	12-09-1996
		EP 0216600 A	01-04-1987
		JP 11326277 A	26-11-1999
		JP 7111398 B	29-11-1995
		JP 62073138 A	03-04-1987
DE 4136462 A	06-05-1993	AT 122919 T	15-06-1995
		DE 59202371 D	29-06-1995
		DK 610419 T	04-09-1995
		EP 0610419 A	17-08-1994
		ES 2072774 T	16-07-1995
		JP 6510862 T	01-12-1994
		WO 9308903 A	13-05-1993
EP 0546916 A	16-06-1993	FR 2684998 A	18-06-1993
		JP 6056899 A	01-03-1994
		SG 52497 A	28-09-1998
		US 5928484 A	27-07-1999
US 5626757 A	06-05-1997	US 5874005 A	23-02-1999
		EP 0748247 A	18-12-1996
		JP 10501727 T	17-02-1998
		WO 9522390 A	24-08-1995
		US 5964996 A	12-10-1999

THIS PAGE BLANK (USPTO)